5-7 December 2017

London, UK

Save £850 – Register Now

Speakers

Expand/Collapse

Jean Viallet
CEO
Inovotion

Frank Schnieders
CEO
Provecs Medical

Frank Schnieders is founder and CEO of Provecs Medical in Hamburg, Germany. He has more than 15 years of experience in biopharmaceutical industry and entrepreneurship. As a biochemist, his focus in more than 20 years of research in the areas of gene therapy, biomedical and clinical research has been the translation of his research into novel treatment options for cancer patients. He authored numerous scientific publications, filed more than 30 patents related to gene and immunotherapy, was dedicated business awards, and is member of CIC, CIMT, SITC. With a PhD in human genetics from the Medical School Hanover, postdoctoral experience in gene therapy and molecular medicine at the Max-Planck-Institute, Berlin, he started his own research group at the University Medical Center in Hamburg-Eppendorf and founded Provecs Medical as a spin-out. In 2016, the first immune-oncology product Immunalon® entered a development and license cooperation with a pharma partner towards clinical testing.

Day One

Wednesday, 6th December 2017

09.40 | How to Achieve Predictability in Development and Monitoring of Tumour Microenvironment Directed Therapies?

Michael Rugaard Jensen
Head of Drug Discovery Pharmacology
Novartis

Michael Rugaard Jensen has a Ph.D. degree in molecular and cellular biology combined with an extensive experience in genetically engineered mice and more than 13 years of leading Oncology Drug Discovery efforts. Michael has for the past 5 year lead the Drug Discovery Pharmacology team that is using a diverse set of innovative in vivo technologies to ensure delivery of novel treatments for cancer patients.

Day Two

Thursday, 7th December 2017

09.40 | Discovering Resistance Mechanisms by Insertional Mutagenesis in Mice

Sara Colombetti, Ph.D
Head of Oncology Discovery Pharmacology
Roche Innovation Center

Sara Colombetti received her Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy) focusing on the characterization of the molecular mechanisms of T  cell function and regulation. She then spent the next 5 years developing cancer CD8 T cell vaccines based on lentiviral vectors and VLP technologies at the Ludwig Institute for Cancer Research (Lausanne Branch, Switzerland) and at Cytos Biotechnology (Schlieren, Switzerland), respectively. In October 2009 she has joined the Oncology Discovery Pharmacology Department of the Roche Innovation Center Zurich (Switzerland), where she was first leading the In Vivo Models group, then the Immunopharmacodynamics and Bioanalytics & Pharmacokinetics Unit. Since the end of 2016 she has been leading the Oncology Discovery Pharmacology Department, responsible for all pre-clinical in vivo studies run within the Roche Innovation Center Zurich, focusing on cancer immunotherapy approaches.

Pre-Conference Workshop Day

5th December, 2017

13.00 |

Humanised Mouse Models: Advantages and Pitfalls in Preclinical Assessment of Cancer Immunotherapy

Day One

Wednesday, 6th December 2017

16.40 | Humanised Mouse Models for Immunotherapy Pipeline Advancement

Elizabeth Hardaker
Team Leader
AstraZeneca

Elizabeth Hardaker did her PhD and post doc in respiratory diseases at the National Heart and Lung Institute (NHLI) Imperial college.  After this Elizabeth moved to Novartis Institute for Biomedical Research in the Respiratory disease area.  Within this job role she developed a wide variety of in vivo models to investigate immune stimulatory agents that would enhance clearance of bacterial and viral infection.  Subsequently Elizabeth moved to Evotec as a group leader where amongst other roles she was biology lead for an immune oncology project.  Elizabeth is now a Team Leader at Astra Zeneca within the oncology in vivo team.  As part of this role Elizabeth supports the strategy to introduce and characterise models to enable the group to actively support immune targeting therapies.

Day One

Wednesday, 6th December 2017

15.10 | Role of Genetically Engineered Mouse Models in Drug Discovery

Anita Seshire, Ph.D
Head of Laboratory, Translational Innovation Platform Oncology
Merck

Biomolecular engineer by training, graduated in pharmacy, expert in cancer stem cells, started with leukemic stem cells research funded by a José Carreras fellowship and now 8 years with Merck Biopharma in cancer stem cells and oncology/ immuno-oncology research.

Day One

Wednesday, 6th December 2017

10.40 | Utilising Multicellular 3D Models for Preclinical Drug Discovery

Andreas Lingnau
Principal Scientist
Genmab

Andreas Lingnau gained a diploma in Biology from the University of Bochum and Bonn in 1993, before working in the Ph.D. project at the GBF Braunschweig, Germany, in the group of Juergen Wehland. Project: “Characterization of invasion mechanisms of Listeria monocytogenes” He then conducted postdoc research at the Washington University – School of Medicine,  within the project “Endocytic traffic of African Trypanosomes”. After which, he worked as a Group Leader at the Tumour Biology Center, ProQinase, in Freiburg, Germany, from 2001-2010.  Until 2014, he was the head of the the "In Vivo Pharmacology" Department at ProQinase. In charge of coordination and project management of in vivo studies using subcutaneous, orthotopic, and metastasis in vivo cancer models, as well as Development of tools to evaluate novel test compounds. From 2014, he has been a Principal Scientist at Genmab, Utrecht, The Netherlands, in the “Translational Research in Pharmacology (TR&P)”, responsible for the planning and conduction of in vivo projects testing the efficacy of novel antibodies and antibody formats in Oncology.

Day Two

Thursday, 7th December 2017

11.40 | Evaluation of a “PDX Clinical Trial” as Tool for Predicting Efficacy in Combination with Identification of Biomarkers

Dr. María José Oliva Martin
Senior Scientist
Immunocore

Dr. María José Oliva Martin is a Senior Scientist in the Preclinical Cell Biology Group at Immunocore Ltd. After graduating in Pharmacy at the University of Seville, she completed an MPhil in Translational Medicine and Therapeutics at the University of Cambridge. She conducted her PhD between the University of Seville, the University of Cambridge and the Karolinska Institute, with a focus on the role of caspases in monocyte activation and its potential in the treatment of inflammatory response syndromes. She first came across CRISPR during her postdoctoral work at the University of Oxford, where she knocked out a differentiation related protein in stem cells. At Immunocore, she has continued in the field of immunotherapy, where she is currently working across different programmes applying CRISPR to specificity testing.

Day One

Wednesday, 6th December 2017

12.40 | Incorporating CRISPR into the pre-clinical testing of TCR-based biologic drug candidates

Dr. Vinagolu Rajasekhar
Senior Research Scientist,
Memorial Sloan Kettering Cancer Center

Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service.  Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials.

Day Two

Thursday, 7th December 2017

14.10 | How To Advance PDX Tumour Biology Platforms Towards Enhancing Present Cancer Therapy Approaches?

Daniel Hynes
Preclinical Manager
E-therapeutics

Daniel has over 14 years drug discovery and development experience working in biotech, contract research and consultancy organisations on projects ranging through discovery into development. Daniel spent the early part of his career at Evotec in the UK specialising in in vitro DMPK. He then moved to Fulcrum Pharma in 2006, initially as a Preclinical Project Manager working across multiple indications and then subsequently as an Early Phase Product Strategy Consultant working across Preclinical, Project Management and Clinical Development. Daniel moved to e-Therapeutics in 2012 where he took up the position of Preclinical Manager taking responsibility for preclinical studies for discovery and development projects. Since 2006 Daniel has contributed towards nine successful first time in man enabling preclinical development programmes of work and has also contributed towards the development of three successfully registered products in the areas of advanced gastric cancer, malaria and HAE.

Day One

Wednesday, 6th December 2017

10.10 | The Application of Network Driven Drug Discovery to Identify Novel First in Class Small Molecules Across a Variety of Oncology Indications

Hitesh Mistry
Senior Research Fellow
University of Manchester

Hitesh is an applied mathematician who has worked within the pharmaceutical/biotech industry for over a decade working on projects from discovery through to late-stage clinical development within Oncology. He is currently a part-time Senior Research Fellow at the University of Manchester where he supports numerous projects at different stages of discovery/development at Cancer Research UK and the Christies NHS Trust. In addition to this he also holds a part-time role at Systems Forecasting where he consults for numerous SMEs.

Day Two

Thursday, 7th December 2017

12.10 | Sophisticatedly Simple Approaches to Dose Translation

Dr. Neta Moskovits
Head of The Galilee Translational Cancer BioBank

Dr. Neta Moskovits, the head of the "Galeele translational cancer Bio-bank" (Israel), has been working for 13 years in the field of molecular biology of cancer and has extensive experience in working and establishing models for in-vivo and in-vitro cancer research. Her Ph.D. at Weizmann Institute of Science (Israel) focused on the tumor-stroma interactions and recapitulating the complex biology and microenvironment of the tumor tissue. She participated in a multinational project on behalf of the EU Consortium- PREDECT, which focused on the establishment of advanced models and experimental platforms for pre-clinical development of drugs. She moved to the field of personalized medicine and translational cancer research, and join the founder team of the "Galeele translational cancer Bio-bank" (of PDX models) and Rabin medical center. The Bio-Bank collection include more than 400 PDX models, and focusing on establishment novel humanized mice models to increase the translational relevance of the PDX models.

Day One

Wednesday, 6th December 2017

17.10 | PDX Models Recapitulate Clinical Tumour Progression

Niina Veitonmäki
Head In Vivo Oncology
Alligator bioscience

Dr. Veitonmäki is the Head of In vivo Oncology Department at Alligator Bioscience, a biotech company located in Lund, Sweden. Alligator Bioscience focuses on developing mono and bispecific antibodies for tumor directed immunotherapy of cancer. Dr. Veitonmäki joined Alligator bioscience 2011 and her role in the company is to lead the in vivo activities of drug development projects. In addition, she is the scientific lead for the bispecific ATOR-1015 project. Dr. Veitonmäki earned her PhD 2003 at Karolinska Institutet in the field of tumor oncology and has after her post-doc focused her career on antibody based therapies in oncology and immuno-oncology within different biotech companies.

Day Two

Thursday, 7th December 2017

12.40 | Preclinical Models Evaluating the Bispecific Immunomodulatory Antibody ATOR-1015 Targeting OX40 and CTLA

Shannon Burke
Scientist
Medimmune

Cancer Immunologist with previous experience in lymphocyte development, virus and tumour immunology at the Wellcome Trust Sanger Institute and the Babraham Institute. Now working in pre-clinical oncology at Medimmune, Cambridge. Long-standing interest in complex in vitro systems to better model clinical scenarios.

Day Two

Thursday, 7th December 2017

10.10 | A Slice of Reality: Using Tumour Slices to Study the Tumour Microenvironment

Sheila Krishnadath
Professor of Gastroenterology, AMC
University of Amsterdam

Dr. Krishnadath is a Professor of Translational Gastroenterology at the Cancer Center pf Amsterdam. She has a long track record on clinical and fundamental/translational research on Barrett’s esophagus and the associated esophageal adenocarcinoma. studying Barrett’s esophagus and biomarkers of progression to cancer. She has also been interested in developing and improving immunotherapy by understanding and manipulating the tumor immune environment in esophageal adenocarcinoma. She has been developing targeted therapies against Barrett cancers and Barrett esophagus and developed several models to study these diseases.

Day One

Wednesday, 6th December 2017

13.10 | Remodelling Barrett’s Metaplasia in a Novel In Vivo Organoid Model

Silvia Calpe
Postdoc, AMC
University of Amsterdam

She carried out her doctoral studies at Harvard Medical School where she focused on the generation of immunotherapies as well as developing animal models of autoimmune diseases. She is currently a postdoctoral fellow at the Center for Experimental and Molecular Medicine, at the AMC, Amsterdam. She is involved in assessing the therapeutic potential of llama-derived antibodies in esophageal adenocarcinoma. She is also leading projects to develop novel models of esophageal adenocarcinoma and its preneoplastic condition barrett’s esophagus.

Day Two

Thursday, 7th December 2017

10.40 | Targeting the Tumour Microenvironment Signals in a Xenograft Model of Oesophageal Adenocarcinoma

Gavin Bennett
Head of Preclinical Development, AMC
University of Amsterdam

Gavin Bennett is Head of Preclinical Development at Bicycle Therapeutics in Cambridge, UK. He is responsible for managing the preclinical development of Bicycle’s novel therapeutic programmes. Bicycle Therapeutics is developing novel constrained bicyclic peptide (Bicycle) peptides. One application of the technology is the development of Bicycle Drug Conjugates for Oncology, allowing targeted delivery of cytotoxic payloads. Gavin has a PhD in Pharmacology from King’s College London and has worked across therapeutic areas, including oncology, inflammation and CNS disease, developing small molecules, large molecules (antibodies) and now mid-sized molecules (bicyclic peptides). Prior to Bicycle Therapeutics, Gavin led preclinical and pharmacology programmes for companies such as Cellzome, UCB-Celltech, Rhone-Poulenc Rorer.

Day Two

Thursday, 7th December 2017

14.40 | Development of BT1718, a Bicycle Drug Conjugate (BDC) For Solid Tumours

Dr. Olaf Hardt
Manager R&D Oncology
Miltenyi Biotec

Day Two

Thursday, 7th December 2017

09.10 | Isolation of Tumour Cells and Tumour-Infiltrating Immune Cell Subpopulations for Optimised Downstream Analysis

Marie Törngren
Head of Pharmacology
Active Biotech AB

I received my PhD in functional morphology from Department of Zoology at Lund University, Sweden. I have more than 15 years of experience from the Pharmaceutical and Biotech industry within the areas of autoimmunity, inflammation and oncology. I´m currently Head of Pharmacology at Active Biotech AB, a biotechnology company based in Lund and focused on development of pharmaceutical products within the immuno-oncology area. In my current research I utilize syngeneic and humanized models to investigate how the interaction of immune cells can be modulated by small molecule compounds to inhibit tumor growth and metastasis.

Day One

Wednesday, 6th December 2017

15.40 | Developing an in vivo model for Proof of Concept of small molecules targeting the myeloid compartment

Neal Goodwin
Vice President Corporate Research
Champions Oncology

Day One

Wednesday, 6th December 2017

12.10 | How To Advance PDX Tumour Biology Platforms for Drug Advancement

Rajendra Kumari
CSO
Crown Bioscience

Day One

Wednesday, 6th December 2017

09.10 | Identifying Responsive Patient Populations in the Preclinic: Adopting Clinically-Relevant Models Across Oncology Therapeutics

James Keck
Senior Director In Vivo Pharmacology
Jackson

Day One

Wednesday, 6th December 2017

14.40 | Utilising Sophisticated Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies